Search Result

Pathways Recommended:	JAK/STAT Signaling

Results for "

JAK/HDAC-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HDAC (69) JAK (251) Acyltransferase (1) Adenosine Receptor (1) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (4) Apoptosis (67) Arginase (1) Aurora Kinase (3) Autophagy (20) Bacterial (7) Bcr-Abl (4) Biochemical Assay Reagents (1) BMX Kinase (1) Btk (11) CDK (9) Cholinesterase (ChE) (1) COX (3) Cytochrome P450 (2) Deubiquitinase (2) Dopamine Receptor (1) Drug Metabolite (2) EGFR (8) Endogenous Metabolite (4) Epigenetic Reader Domain (2) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (3) FGFR (1) FLT3 (17) Fungal (7) G-quadruplex (1) GSK-3 (4) HBV (1) HCV (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (2) IFNAR (3) iGluR (1) IKK (4) Influenza Virus (2) Interleukin Related (6) Isotope-Labeled Compounds (7) Itk (1) JNK (2) Keap1-Nrf2 (4) LRRK2 (1) MEK (2) MicroRNA (1) Microtubule/Tubulin (5) Mitochondrial Metabolism (1) Mitophagy (6) Monoamine Oxidase (1) mTOR (2) nAChR (1) NF-κB (5) NO Synthase (2) Orthopoxvirus (1) Oxidative Phosphorylation (1) p38 MAPK (4) PAK (1) Parasite (1) PARP (3) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (5) Pim (1) PKC (1) Polo-like Kinase (PLK) (2) PROTACs (12) Reactive Oxygen Species (1) RET (3) RIP kinase (1) SHP2 (1) Sirtuin (4) Small Interfering RNA (siRNA) (9) Src (2) STAT (35) STING (1) Syk (8) TGF-β Receptor (2) TNF Receptor (1) Toll-like Receptor (TLR) (1) Topoisomerase (2) Trk Receptor (1) Tyrosinase (1) VEGFR (3) Virus Protease (1)
By Research Areas:	Cancer (233) Cardiovascular Disease (3) Infection (10) Inflammation/Immunology (139) Metabolic Disease (4) Neurological Disease (8)
Click Chemistry:	Alkynes (6)

378

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: JAK HDAC AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111471A

JAK-IN-5 hydrochloride

JAK Inflammation/Immunology

JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283 ^[1].

JAK-IN-5 hydrochloride	JAK	Inflammation/Immunology
JAK-IN-5 hydrochloride is an inhibitor of *JAK* extracted from patent US20170121327A1, compound example 283 ^[1].

HY-150772

Tubulin/HDAC-IN-1	Microtubule/Tubulin HDAC Apoptosis Mitochondrial Metabolism	Cancer
Tubulin/HDAC-IN-1 is a dual tubulin and *HDAC-IN-1* inhibitor through CH/π interaction with tubulin and hydrogen bond interaction with HDAC8. Tubulin/HDAC-IN-1 inhibits tubulin polymerization and selectively inhibits HDAC8 (IC₅₀: 150 nM). Tubulin/HDAC-IN-1 has cytotoxicity against various human cancer cells, also arrests cell cycle in the G2/M phase and induces cell apoptosis. Tubulin/HDAC-IN-1 can be used in the research of hematologic and solid tumors such as neuroblastoma, leukemia ^[1].

HY-111471

JAK-IN-5

JAK Inflammation/Immunology

JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.

JAK-IN-5	JAK	Inflammation/Immunology
JAK-IN-5 is an inhibitor of *JAK* extracted from patent US20170121327A1, compound example 283.

HY-157121

JAK-IN-34	JAK	Inflammation/Immunology
JAK-IN-34 (compound 11n) is a potent against of **JAKs with IC₅₀** values of 0.40, 0.83, 2.10, 1.95 nM target JAK1, JAK2, JAK3, TYK2, respectively. JAK-IN-34 reduces joint swelling with good safety ^[1].****

HY-157011

JAK-IN-33

JAK Inflammation/Immunology

JAK-IN-33 (compound 3 (R)) is a JAK inhibitor ^[1].
HY-14986

JAK-IN-32

JAK Others

JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase ^[1].

JAK-IN-33	JAK	Inflammation/Immunology
JAK-IN-33 (compound 3 (R)) is a *JAK* inhibitor ^[1].

JAK-IN-32	JAK	Others
JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase ^[1].

HY-156535

JAK kinase-IN-1	JAK	Inflammation/Immunology
JAK kinase-IN-1 (Example 1) is a *JAK* inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC₅₀ values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively ^[1].

HY-128450

JAK-STAT-IN-1	JAK STAT	Inflammation/Immunology Cancer
JAK-STAT-IN-1 (compound 1) is a selective *JAK-STAT* inhibitor. JAK-STAT-IN-1 can be used for the research of autoimmune disorder ^[1].

HY-149284

JAK/HDAC-IN-3

JAK HDAC Cancer

JAK/HDAC-IN-3 (13a) is a dual JAK and HDAC inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively ^[1].

JAK/HDAC-IN-3	JAK HDAC	Cancer
JAK/HDAC-IN-3 (13a) is a dual *JAK* and *HDAC* inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively ^[1].

HY-144058

JAK-IN-18	JAK	Inflammation/Immunology
JAK-IN-18 is a potent inhibitor of *JAK. JAK*-IN-18 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2018204238A1, compound 1) ^[1].

HY-144057

JAK-IN-17	JAK	Inflammation/Immunology
JAK-IN-17 is a potent inhibitor of *JAK. JAK*-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1) ^[1].

HY-148060

JAK-IN-21

JAK Cancer

JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively ^[1].

JAK-IN-21	JAK	Cancer
JAK-IN-21 (Example 4) is a selective and potent *JAK* inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively ^[1].

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of PARP and *HDAC*. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and *HDAC1* with IC₅₀s of 19.01, 2.13, 1690 nM, respectively ^[1].

HY-161350

ALK/HDAC-IN-1	Anaplastic lymphoma kinase (ALK) HDAC	Cancer
ALK/HDAC-IN-1 is a dual inhibitor for ALK and HADC6, with IC₅₀s of 16 nM and 1.03 μM, respectively. ALK/HDAC-IN-1 exhibits antitumor activity ^[1].

HY-144315

Snail/HDAC-IN-1	HDAC	Cancer
Snail/HDAC-IN-1 is a potent *Snail/HDAC* dual target inhibitor. Snail/HDAC-IN-1 displays potent inhibitory activity against HDAC1 with an IC₅₀ of 0.405 μM and potent inhibition against Snail with a K_d of 0.18 μM. Snail/HDAC-IN-1 increases histone H4 acetylation in HCT-116 cells and decreases the expression of Snail protein to induce cell apoptosis ^[1].

HY-141701

mTOR/HDAC-IN-1	mTOR HDAC	Cancer
mTOR/HDAC-IN-1 (Compound 50) is a selective mTOR and *HDAC* dual inhibitor with IC₅₀ values of 0.49 and 0.91 nM against mTOR and HDAC1, respectively. mTOR/HDAC-IN-1 can be studied as an anti-cancer agent ^[1].

HY-146160

PARP-1/HDAC-IN-1	PARP HDAC	Cancer
PARP-1/HDAC-IN-1 is a *PARP-1/HDAC6* dual targeting inhibitor with IC₅₀s of 68.90 nM and 510 nM, respectively. PARP-1/HDAC-IN-1 displays remarkable anticancer, anti-migration and anti-angiogenesis activities ^[1].

HY-142706

MAO A/HDAC-IN-1	Monoamine Oxidase HDAC	Cancer
MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and *HDAC. MAO A/HDAC-IN-1* can be used for glioma research ^[1]. MAO A/HDAC-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145851

Top/HDAC-IN-1	HDAC Topoisomerase Apoptosis	Cancer
Top/HDAC-IN-1 (Compound 29b) is a *topoisomerase/HDAC* dual inhibitor with IC₅₀s of 18, 230, 790, 87, and 5250 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, respectively. Top/HDAC-IN-1 exhibits potent antitumor activities against the HCT116 cell line with the IC₅₀ of 180 nM. Top/HDAC-IN-1 efficiently induces apoptosis with G2 cell cycle arrest in HCT116 cells ^[1].

HY-151263

G4/HDAC-IN-1	HDAC G-quadruplex	Cancer
G4/HDAC-IN-1 (compound a6) is a *G4/HDAC* dual-targeting compound. G4/HDAC-IN-1 inhibits intracellular HDAC activity with an IC₅₀ value of 1.1 μM, and induces G4 formation. G4/HDAC-IN-1 inhibits TNBC proliferation and tumor growth in TNBC xenograft model. G4/HDAC-IN-1 can be used for the research of cancer ^[1].

HY-149238

Topo II/HDAC-IN-1	Topoisomerase HDAC Apoptosis	Cancer
Topo II/HDAC-IN-1 (7d) exhibits excellent dual inhibitory activities against Topo II and *HDAC. Topo II/HDAC-IN-1* (8d) induces apoptosis ^[1].

HY-144643

CYP51/HDAC-IN-1	Fungal HDAC Cytochrome P450	Inflammation/Immunology
CYP51/HDAC-IN-1 is a potent, orally active *CYP51/HDAC* dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis ^[1].

HY-143233

PIM-1/HDAC-IN-1	Pim HDAC Apoptosis	Cancer
PIM-1/HDAC-IN-1 (compound 4d) is a *PIM-1* inhibitor, with an IC₅₀ of 343.87 nM. PIM-1/HDAC-IN-1 has strong inhibitory activity and selectivity against HDAC 1 and HDAC 6, with IC₅₀ values of 63.65 and 62.39 nM, respectively. PIM-1/HDAC-IN-1 exhibits apoptosis inducing potential in MCF-7 cell lines. PIM-1/HDAC-IN-1 shows pre-G1 apoptosis and cell cycle arrest at G2/M phase ^[1].

HY-147873

NMDAR/HDAC-IN-1	iGluR HDAC	Neurological Disease
NMDAR/HDAC-IN-1 (Compound 9d) is a dual NMDAR and *HDAC* inhibitor with a K_i of 0.59 μM for NMDAR and IC₅₀ values of 2.67, 8.00, 2.21, 0.18 and 0.62 μM for HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8, respectively. NMDAR/HDAC-IN-1 efficiently penetrates the blood brain barrier ^[1].

HY-151464

SHP2/HDAC-IN-1	SHP2 Phosphatase HDAC	Inflammation/Immunology Cancer
SHP2/HDAC-IN-1 is a dual allosteric *SHP2/HDAC* inhibitor with IC₅₀ values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunoresearch ^[1].

HY-147991

PDE5/HDAC-IN-1	Phosphodiesterase (PDE) HDAC Apoptosis	Cancer
PDE5/HDAC-IN-1 (Compound 26) is a potent phosphodiesterase 5 (PDE5) and *HDAC* inhibitor with IC₅₀ values of 46.3 nM and 14.5 nM, respectively. PDE5/HDAC-IN-1 induces cell apoptosis and shows anticancer activities ^[1].

HY-156094

JMJD3/HDAC-IN-1	HDAC Histone Demethylase Apoptosis	Cancer
JMJD3/HDAC-IN-1 (compound A5b) is a dual inhibitor targeting Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylase (HADC1, IC₅₀=16 nM). JMJD3/HDAC-IN-1 promotes hypermethylation of histone H3K27 and hyperacetylation of H3K9, and also cleaves caspase-7 and PARP to induce apoptosis. JMJD3/HDAC-IN-1 effectively inhibits cancer cell cloning, migration, and invasion ^[1].

HY-143324

A2AAR/HDAC-IN-1	HDAC Adenosine Receptor	Cancer
A2AAR/HDAC-IN-1 (compound 14c) is an orally active, potent and balanced *A_2AAR/HDAC* dual inhibitor, with a K_i of 163.5 nM for A_2AAR and an IC₅₀ of 145.3 nM for *HDAC1. A2AAR/HDAC-IN-1* shows anticancer activity ^[1].

HY-132914

CDK/HDAC-IN-1

CDK Cancer

CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC₅₀ = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.

CDK/HDAC-IN-1	CDK	Cancer
CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and *HDAC6* inhibitory activity of IC₅₀ = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 ^[1].

HY-13827

JAK-IN-1 1 Publications Verification	JAK	Inflammation/Immunology
JAK-IN-1 is a *JAK1/2/3* inhibitor with IC₅₀s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.

HY-100759

JAK2-IN-4

JAK Cancer

JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively ^[1].

JAK2-IN-4	JAK	Cancer
JAK2-IN-4 (compound 16h) is a selective *JAK2/JAK3* inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively ^[1].

HY-111750

JAK-IN-3	JAK	Inflammation/Immunology
JAK-IN-3 (compound 22) is a potent *JAK* inhibitor, with IC₅₀ values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively ^[1].

HY-139807

JAK-IN-14	JAK	Inflammation/Immunology
JAK-IN-14 is a potent and selective *JAK1* inhibitor, with an IC₅₀ of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16) ^[1].

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) ^[1].

HY-143444

JAK-IN-20	JAK	Inflammation/Immunology
JAK-IN-20 is a potent, pan and orally active *JAK* inhibitor with an IC₅₀s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo ^[1].

HY-154994

JAK-IN-30	JAK	Inflammation/Immunology
JAK-IN-30 (compound 31) is a water-soluble *JAK* inhibitor with IC₅₀ values of 2, 15, 18 and 2 nM for *JAK2, JAK1, JAK3* and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) ^[1].

HY-137756

JAK2-IN-6	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells ^[1].

HY-147975

JAK3-IN-12	JAK	Inflammation/Immunology
JAK3-IN-12 (compound 5k) is a highly potent *JAK3* inhibitor with IC₅₀ values of 9.5 nM, 18 nM and 42 nM for JAK3, JAK1 and JAK2, respectively. JAK3-IN-12 can be used for researching rheumatoid arthritis ^[1].

HY-133747

JAK3-IN-9	JAK	Inflammation/Immunology
JAK3-IN-9 is an orally active *JAK3* inhibitor with IC₅₀ value of 1.7 nM. JAK3-IN-9 is highly selective to the *JAK3* signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows good anti-arthritis activity. JAK3-IN-9 can be used in autoimmune disease research ^[1].

HY-161139

JAK1-IN-14	JAK	Inflammation/Immunology
JAK1-IN-14 (Compound 12a) is a potent and selective *JAK1* inhibitor. JAK1-IN-14 inhibits *JAK1* and *JAK2* with an IC₅₀ value of 12.6 nM and 135 nM. JAK1-IN-14 suppresses hepatic fibrosis levels and can be used for the research of liver fibrosis and inflammatory diseases ^[1].

HY-153440

JAK-IN-25	JAK	Cancer
JAK-IN-25 (compound 19) is a potent *JAK* inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research ^[1].

HY-100849

JAK 3i	JAK	Inflammation/Immunology
JAK3i is a highly selective *JAK3* inhibitor (IC₅₀: 0.43 nM). JAK3i forms a covalent bond with a cysteine in JAK3, but not the closely related kinase domains in JAK1, JAK2, or TYK2. JAK3i abolishes IL-2-driven T-cell proliferation in vivo and has the potential for autoimmune disease research ^[1].

HY-19544

JAK3-IN-1	JAK	Cancer
JAK3-IN-1 is a potent, selective and orally active *JAK3* inhibitor with an IC₅₀ of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for *JAK3* than JAK1 (IC₅₀ of 896 nM) and JAK2 (IC₅₀ of 1050 nM) ^[1].

HY-144440

JAK1-IN-9

JAK Cancer

JAK1-IN-9 (compound 23a) is a potent and selective JAK1 inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more ^[1].

JAK1-IN-9	JAK	Cancer
JAK1-IN-9 (compound 23a) is a potent and selective *JAK1* inhibitor with an IC₅₀ of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more ^[1].

HY-116505

JAK1-IN-4	JAK	Cancer
JAK1-IN-4 is a potent and selective *JAK1* inhibitor, with IC₅₀s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC₅₀, 227 nM) ^[1].

HY-156706

JAK-IN-31	JAK	Cancer
JAK-IN-31 (Example 75) is a *JAK* inhibitor with IC₅₀ ranges of ≤0.01µM, ≤0.01µM, 0.01-0.1 µM and ≤0.01µM for *JAK1, JAK2, JAK3* and Tyk2 respectively. JAK-IN-31 can be used in cancer research ^[1].

HY-149296

JAK1-IN-12	JAK	Inflammation/Immunology
JAK1-IN-12 is a selective inhibitor of *JAK1, with IC₅₀* of 0.0246 μM. And IC₅₀s of 0.423 μM, 0.410 μM and 1.12 μM for JAK2, JAK3 and TYK2. JAK1-IN-12 promotes hair growth in mice. JAK1-IN-12 can be used for research of immune and inflammatory diseases ^[1].

HY-146727

JAK3-IN-11	JAK	Inflammation/Immunology
JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active *JAK3* inhibitor with IC₅₀ value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T cell proliferation, is a promising tool for study autoimmune diseases ^[1].

HY-153712

JAK-IN-28

JAK Inflammation/Immunology Cancer

JAK-IN-28 (Compound 111) is a JAK inhibitor. JAK-IN-28 can be used for research of cancer or inflammatory diseases ^[1].

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

419 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 419 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

HY-L156

Autoimmune Disease Compound Library

454 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 454 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

HY-L080

Targeted Therapy Drug Library

107 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 107 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L016

Protein Tyrosine Kinase Compound Library

1045 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1045 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L079

Anti-Blood Cancer Compound Library

2657 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2657 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L017

Stem Cell Signaling Compound Library

1723 compounds

Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.

MCE owns a unique collection of 1723 compounds that can be used for stem cell regulatory and signaling pathway research.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0697

Crocin 5+ Cited Publications CrocIN I	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Lridaceae Plants Crocus sativus L. Functional Molecules Terpenoids Research of Health Products Diterpenoids Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite JAK Apoptosis
Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through *JAK* pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities ^[1] .

HY-N2409

Delphinidin chloride	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Plants Anthocyans Flavonoids other families Microorganisms Solanum melongena L. Phenols Polyphenols Solanaceae Disease Research Fields Cancer	Apoptosis EGFR JAK STAT
Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates *JAK/STAT3* and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC₅₀: 1.3 μM), shutting down downstream signaling cascades ^[1] .

HY-N1405

Cucurbitacin I 5+ Cited Publications ElatericIN B; JSI-124; NSC-521777	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-113573

Protosappanin A PTA	Structural Classification Classification of Application Fields Leguminosae Caesalpinia sappan L. Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	JAK STAT
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses *JAK2/STAT3*-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3 ^[1].

HY-N1356

Reticuline	Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Disease Research Fields Lindera aggregata (Sims) Kosterm.	JAK STAT NF-κB Endogenous Metabolite
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 ^[1]. Reticuline exhibits cardiovascular effects .

HY-N0635

Prim-O-glucosylcimifugin 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Ophryosporus axilliflorus Hieron. Source classification Plants Umbelliferae Inflammation/Immunology Disease Research Fields	NO Synthase COX
Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

HY-N1405R

Cucurbitacin I (Standard) ElatericIN B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity ^[1] .

HY-N2959

Brevilin A 3 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Euchresta horsfieldii (Lesch.) J. Benn. Plants Compositae Disease Research Fields Cancer	JAK STAT Apoptosis Autophagy
Brevilin A is an orally active *STAT3/JAK* inhibitor (STAT3 IC₅₀= 10.6 µM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy ^[1] .

HY-121471

Chrysoeriol 1 Publications Verification	Structural Classification Classification of Application Fields Flavones Metabolic Disease Plants Phyllanthus Flavonoids Phenols Polyphenols Euphorbiaceae Brassicaceae Disease Research Fields Coronopus didymus	Endogenous Metabolite
Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity.

HY-N1447

Ganoderic acid A 4 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Polyporaceae Source classification Plants Endogenous metabolite Disease Research Fields Cancer	Apoptosis Autophagy Endogenous Metabolite
Ganoderic acid A can inhibit of the *JAK-STAT3* signaling pathway, also inhibit proliferation, viability, ROS.

HY-N2963

Broussonin E	Structural Classification Thymelaeaceae Source classification Daphne giraldii Nitsche Phenols Polyphenols Plants	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis ^[1].

HY-N0678

Icaritin 1 Publications Verification AnhydroicaritIN	Flavonols Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Berberidaceae Disease Research Fields Cancer	Autophagy Apoptosis
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[1] ^[3.

HY-N12473

25-Deacetylcucurbitacin A	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants Cucumis melo Linn.	JAK
25-Deacetylcucurbitacin A is a Cucurbitane-Type triterpenoid and has the potential to be an anti-cancer agent and JAK/STAT3 signaling pathway inhibitor ^[1].

HY-N3710

Dehydrocrenatidine Kumujian G; O-MethylpicrasidINe I	Alkaloids Simaroubaceae Source classification Pyridine Alkaloids Plants	JAK Apoptosis
Dehydrocrenatidine, a natural alkaloid, is a specific *JAK* inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain ^[1] .

HY-N1356A

(R)-Reticuline	Structural Classification Alkaloids Source classification Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm.	Others
(R)-Reticuline is an isomer of Reticuline (HY-N1356). Reticuline displays anti-inflammatory and cardiovascular effects through JAK2/STAT3 and NF-κB signaling pathways. Salutaridine is a key intermediate in morphine biosynthesis. Salutaridine can be converted from (R)-Reticuline in the poppy plant. The conversion system relies on membrane-bound cytochrome P-450 enzymes and also requires reducing cofactors NADPH, molecular oxygen, etc ^[1] .

HY-N7452

Coumermycin A1	Structural Classification Microorganisms Antibiotics Source classification	JAK Bacterial Orthopoxvirus
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.

HY-N0705

Curculigoside 5 Publications Verification	Curculigo orchioides Gaertn. Structural Classification Monophenols Neurological Disease Classification of Application Fields Source classification Phenols Plants Disease Research Fields Amaryllidaceae Cancer	JAK STAT NF-κB
Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the *JAK/STAT/NF-κB* signaling pathway ^[1].

HY-N2515

Ginsenoside Rk1 2 Publications Verification	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae	NF-κB PI3K JAK Apoptosis
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures ^[1]. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of *Jak2/Stat3* signaling pathway and NF-κB . Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis ^[1]. Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-N0781

Linderalactone 1 Publications Verification	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Lauraceae Disease Research Fields Lindera aggregata (Sims) Kosterm. Cancer	Apoptosis
Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC₅₀ of 15 µM ^[1] .

HY-N0201

Atractylenolide I 2 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae Disease Research Fields Cancer	Toll-like Receptor (TLR) JAK STAT
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated *JAK2* and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-116035

Nimbolide 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Azadirachta indica A. Juss. Disease Research Fields Meliaceae Cancer	NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways ^[1] .

HY-N10623

5-epi-Arvestonate A	Structural Classification Natural Products Classification of Application Fields Plants Compositae Seriphidium transiliense Disease Research Fields Cancer	Tyrosinase
5-epi-Arvestonate A is a sesquiterpenoid isolated from the whole plants of Seriphidium transiliense. 5-epi-Arvestonate A promotes melanogenic production by activating the transcription of microphthalmia-associated transcription factor (MITF) and tyrosinase family genes. 5-epi-Arvestonate A inhibits the expression of IFN-γ-chemokine through the JAK/STAT signaling pathway in immortalized human keratinocyte (HaCaT) cells ^[1].

HY-16561

Resveratrol Maximum Cited Publications 77 Publications Verification trans-Resveratrol; SRT501	Structural Classification Classification of Application Fields Anti-aging Source classification Vitis vinifera cv. Zalema Plants Vitaceae Infection Microorganisms Functional Molecules Sunscreen Research of Health Products Phenols Polyphenols Cosmetic Research Inflammation/Immunology Disease Research Fields Cancer	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator ^[1] . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-16561R

Resveratrol (Standard) Maximum Cited Publications 77 Publications Verification trans-Resveratrol (Standard); SRT501 (Standard)	Infection Functional Molecules Classification of Application Fields Sunscreen Anti-aging Source classification Research of Health Products Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (Standard) is the analytical standard of Resveratrol. This product is intended for research and analytical applications. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, *JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator ^[1] . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

Species:	Human (6)
Tag:	His (4) Tag Free (1) GST (1)
Source:	P. pastoris (2) Sf9 insect cells (2) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P700583

	JAK1 Protein, Human (P. pastoris, His) JAK1; JAK1A; JAK1B; TyrosINe-proteIN kINase JAK1; Janus kINase 1; JAK-1	Human	P. pastoris
	JAK1 protein is a non-receptor tyrosine kinase that plays a crucial role in IFN-α/β/γ signaling and serves as a kinase partner for IL-2 and IL-10 receptors. It cooperates with the type I interferon receptor IFNAR2 to phosphorylate and activate IFNAR2 upon interferon binding to IFNAR1-IFNAR2. JAK1 Protein, Human (P. pastoris, His) is the recombinant human-derived JAK1 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of JAK1 Protein, Human (P. pastoris, His) is 305 a.a., with molecular weight of 36.9 kDa.

HY-P702721

	JAK3 Protein, Human (sf9, GST) JAK3; Janus kINase 3; tyrosINe-proteIN kINase JAK3; JAK 3; JAK3_HUMAN; JAKL; L JAK; leukocyte Janus kINase; LJAK; tyrosINe proteIN kINase JAK3; Janus kINase 3 (a proteIN tyrosINe kINase, leukocyte); JAK-3; L-JAK	Human	Sf9 insect cells

HY-P701102

	*Janus kinase 2/JAK2 Protein, Human (381aa, His)* JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus ActivatINg KINase 2; Janus kINase 2 (a proteIN tyrosINe kINase); Janus kINase 2; JTK 10; JTK10; kINase JAK2; OTTHUMP00000043260; THCYT3; TyrosINe proteIN kINase JAK2; TyrosINe-proteIN kINase JAK2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P7989

	*Janus kinase 2/JAK2 Protein, Human (His)* JAK2, Janus kINase 2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human (His) is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P702720

Janus kinase 2/JAK2 Protein, Human (sf9)

JAK2; Janus kINase 2; tyrosINe-proteIN kINase JAK2; JTK10; JAK-2; Janus kINase 2 (a proteIN tyrosINe kINase); THCYT3
Human Sf9 insect cells

HY-P71785

	SOCS1 Protein, Human (P.pastoris, His) CISH 1; CISH1; CytokINe INducible SH2 proteIN 1; JAB; JAK bINdINg proteIN; JAK-bINdINg proteIN; Janus kINase bINdINg proteIN ; SOCS 1; TEC INteractINg proteIN 3; Tec-INteractINg proteIN 3; TIP 3	Human	P. pastoris
	The SOCS1 protein is an important negative regulator that inhibits type I and type II interferon signaling as well as cytokines such as IL2, IL4, IL6, and LIF. It downregulates the signaling of the JAK/STAT pathway by inhibiting JAK proteins and IFNGR1. SOCS1 Protein, Human (P.pastoris, His) is the recombinant human-derived SOCS1 protein, expressed by P. pastoris , with N-His labeled tag. The total length of SOCS1 Protein, Human (P.pastoris, His) is 211 a.a., with molecular weight of ~25.6 kDa.

Cat. No.	Product Name	Chemical Structure

HY-50856S

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of *JAK1/JAK2*. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I) ^[1].

HY-W062703S

(Rac)-Ruxolitinib-d9

(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor ^[1].

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-40354S

Tofacitinib-13C3

Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-40354AS

Tofacitinib-d3 citrate
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].

HY-W727879

Upadacitinib-15N,d2

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research ^[1] .

HY-109015S

Tucidinostat-d4
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively[1].

HY-131968

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium ^[1].

HY-16561S1

Resveratrol-13C6

Resveratrol- ¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

HY-16561S

Resveratrol-d4

Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator[1][2][3][4]. Resveratrol is a potent pregnane X receptor (PXR) inhibitor[5]. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model[6]. Resveratrol increases production of NO in endothelial cells[7].

Cat. No.	Product Name	Application	Reactivity

HY-P80726

JAK1 Antibody (YA722) JAK1; JAK1A; JAK1B; TyrosINe-proteIN kINase JAK1; Janus kINase 1; JAK-1	WB, ICC/IF, IP	Human, Rat
JAK1 Antibody (YA722) is a non-conjugated and Mouse origined monoclonal antibody about 133 kDa, targeting to JAK1 (8B8). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Rat.

HY-P80727

JAK2 Antibody (YA330) JAK2; TyrosINe-proteIN kINase JAK2; Janus kINase 2; JAK-2	WB	Human, Mouse
JAK2 Antibody (YA330) is a non-conjugated and Rabbit origined monoclonal antibody about 131 kDa, targeting to JAK2. It can be used for WB assays with tag free, in the background of Human, Mouse.

HY-P82721

JAK3 Antibody (YA2466)

JAK3; TyrosINe-proteIN kINase JAK3; Janus kINase 3; JAK-3; Leukocyte janus kINase; L-JAK
WB, ICC/IF Human

HY-P80829

*Phospho-JAK2 (Tyr1007/1008) Antibody* JAK2; TyrosINe-proteIN kINase JAK2; Janus kINase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
Phospho-JAK2 (Tyr1007/1008) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 131 kDa, targeting to Phospho-JAK2 (Tyr1007/1008). It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80196

JAK1 Antibody	WB, IHC-P, FC	Human, Mouse, Rat
JAK1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 133 kDa, targeting to JAK1. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80421

JAK2 Antibody (YA721)	WB, ICC, IHC-P, FC	Human, Mouse, Rat
JAK2 Antibody (YA721) is a non-conjugated and Mouse origined monoclonal antibody about ~130kDa, targeting to JAK2. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80467

*Phospho-JAK2 (Tyr1007+Tyr1008) Antibody*	WB, ICC, IHC-P, IP	Human, Mouse, Rat
Phospho-JAK2 (Tyr1007+Tyr1008) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 131 kDa, targeting to Phospho-JAK2(Y1007+Y1008). It can be used for WB,ICC,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80728

JNK Antibody AI849689; c Jun N termINal kINase 1; C-JUN kINase 1; c-Jun N-termINal kINase 1; EC 2.7.11.24; JAK 1A; JAK1A; JNK 1; JNK 46; JNK; JNK-46; JNK1A2; JNK21B1/2; MAP kINase 8; MAPK 8; MAPK8; Mitogen activated proteIN kINase 8; Mitogen-activated proteIN kINase 8	WB, IP	Human, Mouse, Rat, Hamster
JNK Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48 kDa, targeting to JNK. It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.

HY-P80897

SOCS1 Antibody SOCS1; SSI1; TIP3; Suppressor of cytokINe signalINg 1; SOCS-1; JAK-bINdINg proteIN; JAB; STAT-INduced STAT INhibitor 1; SSI-1; Tec-INteractINg proteIN 3; TIP-3	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
SOCS1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 24 kDa, targeting to SOCS1. It can be used for ICC/IF,WB,IHC-F,IHC-P,ELISA assays with tag free, in the background of Human, Mouse, Rat.

HY-P80729

JNK1 Antibody (YA720) AI849689; c Jun N termINal kINase 1; C-JUN kINase 1; c-Jun N-termINal kINase 1; EC 2.7.11.24; JAK 1A; JAK1A; JNK 1; JNK 46; JNK; JNK-46; JNK1A2; JNK21B1/2; MAP kINase 8; MAPK 8; MAPK8; Mitogen activated proteIN kINase 8; Mitogen-activated proteIN kINase 8	WB, ICC/IF	Human, Mouse, Rat
JNK1 (1A4) Antibody is a non-conjugated and Mouse origined monoclonal antibody about 48 kDa, targeting to JNK1 (1A4). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80831

Phospho-JNK1 (Thr183/Tyr185) Antibody AI849689; c Jun N termINal kINase 1; C-JUN kINase 1; c-Jun N-termINal kINase 1; EC 2.7.11.24; JAK 1A; JAK1A; JNK 1; JNK 46; JNK; JNK-46; JNK1A2; JNK21B1/2; MAP kINase 8; MAPK 8; MAPK8; Mitogen activated proteIN kINase 8; Mitogen-activated proteIN kINase 8	WB, IP	Human, Rat
Phospho-JNK1 (Thr183/Tyr185) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48 kDa, targeting to Phospho-JNK1 (Thr183/Tyr185). It can be used for WB,IP assays with tag free, in the background of Human, Rat.

Cat. No.	Product Name		Classification

HY-U00277

JAK-IN-10		Alkynes
JAK-IN-10 is a *JAK* inhibitor. JAK-IN-10 can be used for the research of dry eye disorders ^[1]. JAK-IN-10 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-U00318

JAK-IN-11		Alkynes
JAK-IN-11 is a potent and selective *JAK* inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment ^[1]. JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-142706

MAO A/HDAC-IN-1		Alkynes
MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and *HDAC. MAO A/HDAC-IN-1* can be used for glioma research ^[1]. MAO A/HDAC-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153050

JAK-IN-24		Alkynes
JAK-IN-24 is a *JAK* inhibitor, with IC₅₀s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC₅₀ of 86.171 nM ^[1]. JAK-IN-24 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151872

HDAC-IN-48		Alkynes
HDAC-IN-48 is a potent *HDAC* inhibitor. HDAC-IN-48 is a hybrid molecule with great cytotoxic profile (GI₅₀~20 nM). HDAC-IN-48 consists of harmacophores of SAHA and CETZOLE molecules. HDAC-IN-48 induces ferroptosis and inhibits *HDAC* proteins . HDAC-IN-48 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active *HDAC6* inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and *LSD1* inhibitor ^[1]. HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks